Send us a text

Dr. Oren Gilad, Ph.D., is President and Chief Executive Officer of Aprea Therapeutics ( https://aprea.com/ ), a clinical stage, platform biotechnology company focused on the development of novel, synthetic lethality-based therapies, with direct on-target mechanisms of action, and clear clinical pathways, that target various aspects of DNA Damage Response (DDR) Pathways.

Dr. Gilad previously served as President and CEO of Atrin Pharmaceuticals, Inc., leading its transaction with Aprea Therapeutics.

Dr. Gilad brings extensive experience across multiple phases of drug development. During his time at Atrin, he led development from idea through early stage into the clinical stage while securing financing to support pre-clinical and clinical development, regulatory, and intellectual property activities.

Before founding Atrin in 2011, Dr. Gilad authored several high-impact scientific publications over a 13-year academic career, including one demonstrating the importance of the ATR kinase pathway in cancer development and treatment.

Dr. Gilad earned his doctorate in comparative pathology from the University of California at Davis, did his post-doc work at University of Pennsylvania School of Medicine, and his B.S. from the Hebrew University, Jerusalem, Israel.

#Cancer #Oncology #TumorBiology #OrenGilad #ApreaTherapeutics #Biotechnology #DrugDevelopment #Macrocycles #SyntheticLethality #DNADamageResponse #Doylestown #Philadelphia #ATRKinase #WEE1 #BRCA #PARP #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research

Support the show

Send us a text

Dr. Luba Perry, Ph.D. is Co-Founder and CEO of ReConstruct Bio ( https://wyss.harvard.edu/technology/reconstruct/ ), an innovative venture emerging from Harvard’s Wyss Institute ( https://wyss.harvard.edu/team/advanced-technology-team/luba-perry/ ), aimed at redefining the fields of medical reconstruction and aesthetics with an initial application of their groundbreaking technology on breast reconstruction and augmentation. With a multidisciplinary team of experts, the ReConstruct Bio team has developed the BioImplant—a living, bioengineered tissue created from the patient’s own cells, to provide safer, more natural alternative to current standards, which are often associated with significant drawbacks and health concerns.

Dr. Perry also serves as a Senior Scientist at the Wyss Institute for Biologically Inspired Engineering working at the 3D Organ Engineering Initiative since 2018 and is leading a Wyss Validation Project aiming to fabricate vascularized functional tissues for transplantation. Her interest is in tissue and organ engineering, focusing on vascularization and implantation studies utilizing complex surgical models.

Dr. Perry’s background is in molecular biology, pharmacology, and biomedical engineering, with a Bachelor of Science - BS, Biology, Master of Science - MS, Molecular Pharmacology, and a Doctor of Philosophy - PhD, Biotechnology, all from Technion - Israel Institute of Technology. She also has industry experience in a vascular gene therapy company (MGVS, now VESSL Therapeutics).

#LubaPerry #Harvard #WyssInstitute #ReConstructBio #Aesthetics #3DOrganEngineering #BreastReconstruction #BreastAugmentation #Vascularization #Innervation #Fat #AdiposeTissue #BreastImplants #Organogenesis #OrganEngineering #TissueEngineering #Bioengineering #Organs #Tissues #MolecularPharmacology #Breasts #Nipples
#ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research

Support the show

Send us a text

Dr. Richard Scranton, M.D., M.P.H., is the President of Global Product Development and the Chief Medical Officer of Lyndra Therapeutics ( https://lyndra.com/ ), a company pioneering long-acting oral therapies, designed to deliver medicine for up to a week or longer in an oral form.

Dr. Scranton is responsible for advancing the company's proprietary LYNX™ drug delivery platform ( https://lyndra.com/platform/ ) and evolving and overseeing portfolio strategy, current and future product development from preclinical through commercialization, and external partnerships and alliances.

Dr. Scranton has 20+ years of expertise in pharmaco-epidemiologic research, clinical epidemiology, health services research and clinical trials research.

Prior to joining Lyndra, Dr. Scranton held roles with increasing responsibility at Pacira Pharmaceuticals, including Chief Medical Officer, where he led the global development and advancement of their non-opioid long-lasting injectable local anesthetic. Dr. Scranton also served as Chief Medical Officer at VeroScience, where his responsibilities included all aspects of clinical development, regulatory and pharmacovigilance of their investigational drugs in the metabolic disease and immunological domains.

Dr. Scranton also has served as instructor in medicine at Harvard Medical School and associate physician in the division of aging at Brigham and Women’s Hospital, associate medical director and research consultant for Phase V Technologies, assistant clinical professor of medicine at the Uniformed Services University of the Health Sciences and a senior research fellow at the Massachusetts Veterans Administration Epidemiology, Research and Information Center (MAVERIC).

Dr. Scranton earned a Bachelor of Arts from the University of Tennessee and a Doctor of Medicine from the Quillen College of Medicine at Eastern Tennessee State University. He completed his internship and residency in internal medicine at the Naval Medical Center in Portsmouth, Va, and served as chief resident. He completed his Harvard General Medicine Fellowship and received a Master of Public Health from the Harvard School of Public Health.

#RichardScranton #LyndraTherapeutics #LongActing #OralTherapies #Risperidone #Pharmacoepidemiology #MedicationAdherence #RobertLanger #BiochemicalEngineering #Schizophrenia #OpioidUseDisorder #PregnancyPrevention #Pharmacokinetics #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research

Support the show